Braidwell LP Takes $18.80 Million Position in Immatics (NASDAQ:IMTX)

Braidwell LP acquired a new stake in shares of Immatics (NASDAQ:IMTX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,647,565 shares of the company’s stock, valued at approximately $18,799,000. Braidwell LP owned about 1.38% of Immatics at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. AlphaCentric Advisors LLC grew its holdings in shares of Immatics by 14.3% during the second quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company’s stock valued at $232,000 after buying an additional 2,500 shares during the last quarter. Quarry LP purchased a new stake in shares of Immatics during the second quarter valued at $99,000. Forefront Analytics LLC purchased a new stake in shares of Immatics during the second quarter valued at $139,000. The Manufacturers Life Insurance Company grew its holdings in shares of Immatics by 9.3% during the third quarter. The Manufacturers Life Insurance Company now owns 164,766 shares of the company’s stock valued at $1,880,000 after buying an additional 13,997 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Immatics by 13.9% during the second quarter. The Manufacturers Life Insurance Company now owns 150,769 shares of the company’s stock valued at $1,752,000 after buying an additional 18,354 shares during the last quarter. 64.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Immatics in a research report on Thursday, September 5th. The Goldman Sachs Group upgraded shares of Immatics to a “strong-buy” rating in a research report on Monday. Piper Sandler assumed coverage on shares of Immatics in a research report on Monday, October 7th. They set an “overweight” rating and a $19.00 target price for the company. Finally, Bank of America decreased their target price on shares of Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, November 19th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $16.67.

Immatics Stock Performance

Shares of Immatics stock opened at $7.91 on Friday. The firm has a 50-day simple moving average of $9.54 and a two-hundred day simple moving average of $11.07. The company has a market cap of $944.14 million, a P/E ratio of -11.98 and a beta of 0.78. Immatics has a fifty-two week low of $7.46 and a fifty-two week high of $13.77.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.